Euretina Logo, Links to homepage.
Euretina Logo, Links to homepage.
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • September 10, 2021
  • 2021 Abstracts

Hypothetical anti-vascular endothelial growth factor switch in neovascular age-related macular degeneration: A post hoc analysis of the ARIES study

Author: Gábor Márk Somfai (Switzerland)

Co-authors: Cengiz Türksever, Susanne Oesch, Tobias Machewitz, Sandrine Zweifel, Pascal W. Hasler

Purpose

The purpose of this analysis was to explore functional and anatomic outcomes (best-corrected visual acuity [BCVA] and central retinal thickness [CRT]) in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) who were treated with intravitreal aflibercept (IVT-AFL) for up to 104 weeks, but who were identified retrospectively as meeting criteria for a hypothetical switch at Week 24.

Setting/Venue

This post hoc analysis was based on patient data from ARIES (NCT02581891): a randomized, open-label, active-controlled, Phase 3b/4 study that compared the efficacy of two different proactive, individualized treat-and-extend (T&E) regimens of IVT-AFL.

Methods

In ARIES, patients received three initial monthly doses of 2 mg IVT-AFL, followed by an injection after an 8-week treatment interval (Week 16). At Week 16, patients were randomized 1:1 to early-start T&E (IVT-AFL T&E from Week 16 adjusted in 2-week steps) or late-start T&E (IVT-AFL every 8 weeks until Week 48, then T&E from Week 48) with a maximum treatment interval of 16 weeks. Anatomic criteria for extending treatment intervals were the absence of intraretinal fluid (IRF), absence of new neovascularization or hemorrhage, and subretinal fluid (SRF) not exceeding 50 µm in thickness. The primary endpoint of the study was change in BCVA (Early Treatment Diabetic Retinopathy Study [ETDRS] letters) from randomization (Week 16) to Week 104. This post hoc analysis was conducted to describe BCVA and CRT up to Week 104 in patients in the early-start T&E arm who did and did not meet the criteria for a hypothetical switch at Week 24. Criteria for switch, based on clinical practice, were the presence of IRF and/or SRF with central involvement and a next planned treatment interval of ≤8 weeks at Week 24.

Results

In the per-protocol set (n=106), 41 patients (baseline: BCVA, 60.6 letters; CRT, 464.8 μm) met the criteria for a hypothetical switch at Week 24 and 65 patients did not (baseline: BCVA, 60.0 letters; CRT, 453.4 μm). In the switch group, at Week 24, SRF with central involvement was present in 33/41 (80.5%) patients and IRF with central involvement was present in 12/41 (29.3%) patients. Mean (95% CI) change in BCVA from baseline at Week 24 was +6.1 (3.4, 8.8) letters in patients meeting switch criteria and +6.6 (4.7, 8.6) letters in patients not meeting switch criteria; changes at Week 52 were +8.2 (5.0, 11.3) and +7.5 (5.3, 9.7) letters, respectively, and at Week 104 were +5.7 (1.3, 10.1) and +3.4 (0.1, 6.7) letters. Mean (95% CI) change in CRT from baseline in patients who did and did not meet switch criteria was ‒152.0 (‒186.1, ‒117.9) and ‒173.1 (‒203.5, ‒142.6) μm, respectively, at Week 52, and ‒138.3 (‒175.7, ‒101.0) and ‒176.2 (‒212.0, ‒140.4) μm, respectively, at Week 104.

Conlusions

In ARIES, patients with nAMD who could have hypothetically switched anti-VEGF treatment, initial improvements in BCVA were maintained with continued proactive, individualized T&E IVT-AFL therapy. Our results suggest that there is limited rationale for switching treatment-naïve nAMD patients on IVT-AFL during the early course of the therapy since, with continuous proactive treatment, comparable visual gains can be achieved by these patients compared with those who initially respond well on a T&E regimen. As the ARIES study follow-up was 104 weeks, further long-term studies are needed to determine the relevance of our findings over a longer time period.

Financial Disclosure

Gábor Márk Somfai: Consultant for Allergan, Bayer, and Novartis Cengiz Türksever: Consultant for Allergan, Bayer, and Novartis Susanne Oesch: Employee of Bayer (Schweiz) AG Tobias Machewitz: Employee of Bayer AG Sandrine Zweifel: Consultant: Bayer Healthcare Pharmaceuticals, Novartis Pharma AG, and Roche Diagnostics; Speaker: Bayer Healthcare Pharmaceuticals, and Novartis Pharma AG Pascal W. Hasler: Speaker: Bayer, Novartis, and Topcon

Comments

-
PrevPrevious
NextNext
Euretina Logo, Links to homepage.

European Society of Retina Specialists c/o Congrex Switzerland
Reinacherstrasse 131
4053 Basel
Switzerland

T +41 61 686 77 91
F +41 61 686 77 88

General Enquires: [email protected]

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2026 All rights reserved

  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login